Apollo Health Ventures — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Bionyrabionyra.cominJun 2026 · $165M✓ verified
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.
BiotechHealthtech
Frédéric Marrache(Co-founder & CEO)in
Co-investorsJeito CapitalSanofi VenturesSofinnova PartnersVIVES PartnersSixty Degree Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.